Lisata Therapeutics (LSTA) Expected to Release Earnings on Thursday

Lisata Therapeutics (NASDAQ:LSTA) is projected to issue its results before the market opens on Thursday, November 5th. Analysts expect Lisata Therapeutics to announce earnings of ($1.1250) per share and revenue of $0.66 million for the quarter.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.32) EPS for the quarter.

Lisata Therapeutics Price Performance

Shares of NASDAQ:LSTA opened at $1.09 on Wednesday. The firm has a fifty day moving average of $1.37 and a two-hundred day moving average of $2.97. Lisata Therapeutics has a 12-month low of $0.96 and a 12-month high of $5.07.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors.

Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively.